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A B S T R A C T
Background
Cardiovascular disease (CVD) is the most prevalent complication of type 2 diabetes with an estimated 65% of people with type 2
diabetes dying from a cause related to atherosclerosis. Adenosine-diphosphate (ADP) receptor antagonists like clopidogrel, ticlopidine,
prasugrel and ticagrelor impair platelet aggregation and fibrinogen-mediated platelet cross-linking and may be effective in preventing
CVD.
Objectives
To assess the effects of adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes
mellitus.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 2, 2011), MEDLINE
(until April 2011) and EMBASE (until May 2011). We also performed a manual search, checking references of original articles and
pertinent reviews to identify additional studies.
Selection criteria
Randomised controlled trials comparing an ADP receptor antagonist with another antiplatelet agent or placebo for a minimum of 12
months in patients with diabetes. In particular, we looked for trials assessing clinical cardiovascular outcomes.
Data collection and analysis
Two review authors extracted data for studies which fulfilled the inclusion criteria, using standard data extraction templates. We sought
additional unpublished information and data from the principal investigators of all included studies.
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Main results
Eight studies with a total of 21,379 patients with diabetes were included. Three included studies investigated ticlopidine compared to
aspirin or placebo. Five included studies investigated clopidogrel compared to aspirin or a combination of aspirin and dipyridamole,
or compared clopidogrel in combination with aspirin to aspirin alone. All trials included patients with previous CVD except the
CHARISMA trial which included patients with multiple risk factors for coronary artery disease. Overall the risk of bias of the trials
was low. The mean duration of follow-up ranged from 365 days to 913 days.
Data for diabetes patients on all-cause mortality, vascular mortality and myocardial infarction were only available for one trial (355
patients). This trial compared ticlopidine to placebo and did not demonstrate any statistically significant differences for all-cause
mortality, vascular mortality or myocardial infarction. Diabetes outcome data for stroke were available in three trials (31% of total
diabetes participants). Overall pooling of two (statistically heterogeneous) studies showed no statistically significant reduction in the
combination of fatal and non-fatal stroke (359/3194 (11.2%) versus 356/3146 (11.3%), random effects odds ratio (OR) 0.81; 95%
confidence interval (CI) 0.44 to 1.49) for ADP receptor antagonists versus other antiplatelet drugs. There were no data available from
any of the trials on peripheral vascular disease, health-related quality of life, adverse events specifically for patients with diabetes, or
costs.
Authors’ conclusions
The available evidence for ADP receptor antagonists in patients with diabetes mellitus is limited and most trials do not report outcomes
for patients with diabetes separately. Therefore, recommendations for the use of ADP receptor antagonists for the prevention of CVD
in patients with diabetes are based on available evidence from trials including patients with and without diabetes. Trials with diabetes
patients and subgroup analyses of patients with diabetes in trials with combined populations are needed to provide a more robust
evidence base to guide clinical management in patients with diabetes.
P L A I N L A N G U A G E S U M M A R Y
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in patients with type 2 diabetes
mellitus
Patients with type 2 diabetes have a much higher risk of strokes and heart attacks than the general population. Most strokes and
heart attacks are caused by blood clots. Adenosine-diphosphate (ADP) receptor antagonists are drugs which prevent the aggregation
(’clumping’) of platelets and consequently reduce the formation of blood clots. These medications are used to prevent cardiovascular
disease such as heart attacks and strokes in the general population. This review assessed if these medications would be useful in patients
with diabetes. We included eight trials with 21,379 patients and a mean duration of follow-up ranging from 365 to 913 days. Specific
data for patients with diabetes were only available in full for one of these trials and partial data were available for two trials. Analysis of
the available data demonstrated that adenosine-diphosphate receptor antagonists (such as clopidogrel, prasugrel, ticagrelor, ticlopidine)
were not more effective than other blood thinning drugs or placebo for death from any cause, death related to cardiovascular disease,
heart attacks or strokes. There was no available information on the effects of adenosine-diphosphate receptor antagonists on health-
related quality of life, adverse effects specially for people with diabetes, or costs. The use of adenosine-diphosphate receptor antagonists
in patients with diabetes needs to be guided by the information available from trials which included patients with and without diabetes.
All future trials on adenosine-diphosphate receptor antagonists should include data which relate specifically to patients with diabetes
in order to inform evidence-based clinical guidelines.
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B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a defect in
insulin secretion, insulin action, or both. A consequence of this is
chronic hyperglycaemia (that is elevated levels of plasma glucose)
with disturbances of carbohydrate, fat and protein metabolism.
Long-term complications of diabetes mellitus include retinopa-
thy, nephropathy and neuropathy. The risk of cardiovascular dis-
ease is increased. For a detailed overview of diabetes mellitus,
please see under ’Additional information’ in the information on
the Metabolic and Endocrine Disorders Group in The Cochrane
Library (see ’About’, ’Cochrane Review Groups (CRGs)’). For an
explanation of methodological terms, see the main glossary in The
Cochrane Library.
Diabetes, cardiovascular disease and the role of
platelets
The most prevalent complication of type 2 diabetes mellitus is
cardiovascular disease (CVD). It is estimated that 65% of patients
with type 2 diabetes die of a cause related to atherosclerosis (Gu
1998). Risk of mortality and morbidity due to myocardial infarc-
tion, stroke and peripheral arterial disease are two- to four-fold
increased compared with the general population. Once diagnosed
with having diabetes, overall survival is comparable to a patient
with a prior myocardial infarction (Haffner 1998).
Given the upcoming pandemic of patients with diabetes, world
wide prevalence is expected to increase from 2.8% in 2000 to
4.4% in 2030 (Wild 2004), cardiovascular disease will continue
to be responsible for a large proportion of global healthcare ex-
penditures. This stresses the need for preventive measures. In the
development of a cardiovascular event, platelets play an important
role. Platelet adhesion and subsequent activation on dysfunctional
endothelium fuel the inflammatory process in the atherosclerotic
plaque. After disruption of the plaque, large aggregates of platelets
lead to vessel occlusion. In the patient with diabetes, anti-aggrega-
torymechanisms in the endothelium are impaired (Ceriello 2004).
Platelets are more susceptible to activation and aggregation (Kutti
1986) and antifibrinolytic activity is attenuated (Colwell 2003).
Description of the intervention
Adenosine-diphosphate (ADP) is a platelet activator that is re-
leased from red blood cells, activated platelets and damaged en-
dothelial cells which induces platelet adhesion and aggregation
(Kam 2003). ADP receptor antagonists noncompetitively and ir-
reversibly inhibit platelet ADP receptors preventing platelet activa-
tion. This prevents the activations of the glycoprotein IIb/IIIa re-
ceptor complex and prolongs bleeding time, impairs platelet aggre-
gation and fibrinogen-mediated platelet cross-linking (Goodwin
2011). The result is a 50% to 70% inhibition of platelet fibrino-
gen binding achieved after three to five days (Kam 2003).
Adverse effects of the intervention
Gastrointestinal side effects and skin rashes are common. Neu-
tropenia and thrombotic thrombocytopenic purpura are signifi-
cant but rarely fatal adverse events. Recovery of platelet function is
delayed after discontinuation of the medication for approximately
three to seven days (Kam 2003). In terms of cost, ADP receptor
antagonists are considerably more expensive than aspirin.
How the intervention might work
There are clues that ADP receptor antagonists are superior to as-
pirin in preventing cardiovascular disease. In a Cochrane review,
clopidogrel and ticlopidine were slightly, but significantly, more
effective than aspirin in preventing serious vascular events in high-
risk patients (previous clinical manifestations of cardiovascular dis-
ease) (Sudlow 2009). Other evidence was derived from an analysis
of the diabetic subgroup in theCAPRIE-study. In that trial, 15.6%
of patients with diabetes experienced a vascular endpoint versus
17.7% in the aspirin group (P = 0.042). In addition, patients in
the clopidogrel group had less bleeding events: 1.8% versus 2.8%
in the aspirin group (P = 0.031) (Bhatt 2002).
Why it is important to do this review
Despite the evidence for possible advantages, the role of ADP
receptor antagonists in the treatment of patients with diabetes
seems to be limited. A recent position statement by the American
Diabetes Association suggested the use of clopidogrel only in case
of allergy for aspirin or in combination therapy with aspirin for
one year after acute coronary syndrome (ADA 2011). The high
costs of ADP receptor antagonists seem to be the major reason
for the modest position these drugs have in treatment strategies.
Evidence from systematic reviews and meta-analyses is lacking for
ADP receptor antagonists in patients with diabetes. To value the
use of these agents in the treatment of patients with diabetes, a
well-designed systematic review is needed.
O B J E C T I V E S
To assess the effects of adenosine-diphosphate (ADP) receptor an-
tagonists for the prevention of cardiovascular disease in type 2 di-
abetes mellitus.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials comparing an adeno-
sine-diphosphate (ADP) receptor antagonist with another an-
tiplatelet agent or placebo for a minimum of 12 months. Trials
with blinded trial participants and investigators were preferred,
however, single-blind and unblinded trials were considered. We
included studies published in any language.
Types of participants
Eligible patients were adults (18 years and older) with diabetes
mellitus. Trials which used the current standard criteria to establish
the diagnosis of diabetes at the time of the trial were preferred,
however, we accepted authors’ definitions (ADA 1997;ADA1999;
WHO 1980; WHO 1985; WHO 1998).
Types of interventions
Intervention
Any orally administered ADP receptor antagonist given on a con-
tinuing basis.
Control
Placebo, another antiplatelet agent or no treatment.
Types of outcome measures
Primary outcomes
Mortality
• All-cause mortality.
• Mortality related to cardiovascular events (death from
myocardial infarction, stroke, peripheral vascular disease, or
sudden death).
Cardiovascular events
• Myocardial infarction (fatal and non-fatal).
• Stroke (fatal and non-fatal).
• Peripheral arterial disease.
Secondary outcomes
• Adverse effects, such as any major bleeding event, defined as
intracranial bleeding or bleeding requiring surgical intervention
or transfusion.
• Health-related quality of life, ideally measured with a
validated instrument.
• Costs.
Search methods for identification of studies
Electronic searches
The following sources were used from inception to specified time
for the identification of trials.
• The Cochrane Library (issue 2, 2011).
• MEDLINE (until April 2011).
• EMBASE (until May 2011).
We also searched databases of ongoing trials (
http://www.controlled-trials.com/ with links to several databases
and https://www.clinicaltrialsregister.eu/).
For detailed search strategies please see under Appendix 1.
No additional key words of relevance were detected during any
of the electronic or other searches. Thus, the electronic search
strategies were not modified. Studies published in any language
were included.
Searching other resources
We sought additional unpublished information and data from
the principal investigators of all included trials. We performed an
extensive manual search, checking references of original articles
and pertinent reviews to identify additional studies.
Data collection and analysis
Selection of studies
Two review authors (NV and MVD) independently scanned the
titles and abstracts from the original search. If inadequate infor-
mation was provided in the abstract to determine eligibility, the
full text of the article was obtained. Any disagreement was resolved
through discussion between the reviewers. In studies which did
not report detailed subgroup data about patients with diabetes, we
contacted the principal investigators for additional information.
An adapted PRISMA (preferred reporting items for systematic
reviews and meta-analyses) flow-chart of study selection (Figure
1) (Liberati 2009) is attached.
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Figure 1. Study flow diagram.
Data extraction and management
For studies that fulfilled the inclusion criteria, we extracted relevant
population and intervention characteristics using standard data
extraction templates (for details see ’Characteristics of included
studies; Table 1; Appendix 2; Appendix 3; Appendix 4).
Assessment of risk of bias in included studies
Two authors (NV and MVD) assessed each trial independently.
Disagreements were resolved by consensus, or with consultation
of a third party.
We assessed risk of bias using The Cochrane Collaboration’s tool
(Higgins 2011). We used the following risk of bias criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding (performance bias and detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other bias.
We judged risk of bias criteria as ’low risk’, ’high risk’ or ’un-
clear risk’ and evaluated individual bias items as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). A ’Risk of bias’ figure (Figure 2) and a ’Risk of bias sum-
mary’ figure (Figure 3) are attached.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We assessed the impact of individual bias domains on study results
at endpoint and study levels.
Measures of treatment effect
Dichotomous data are expressed as odds ratios (OR) with 95%
confidence intervals (CI). We planned to calculate the risk dif-
ference (RD) and convert it into the number needed to treat to
benefit (NNTB) or the number needed to treat to harm (NNTH)
taking into account the time of follow-up if the overall estimate
of effect was statistically significant.
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome. However, no such
trial designs were included in this review.
Dealing with missing data
We attempted to obtain relevant missing data from authors and
carefully performed evaluation of important numerical data such
as screened, randomised patients as well as intention-to-treat
(ITT), as-treated and per-protocol (PP) population. We investi-
gated attrition rates, for example drop-outs, losses to follow-up
and withdrawals and critically appraised issues of missing data
and imputation methods (for example, last-observation-carried-
forward (LOCF)).
Assessment of heterogeneity
As there was substantial clinical heterogeneity, study results were
only reported asmeta-analytically pooled effect estimates for stroke
(fatal and non-fatal). We identified heterogeneity by visual inspec-
tion of the forest plots, by using a standard Chi2 test and a signif-
icance level of α = 0.1, in view of the low power of this test. We
specifically examined heterogeneity with the I2 statistic quantify-
ing inconsistency across studies to assess the impact of heterogene-
ity on themeta-analysis (Higgins 2002; Higgins 2003), where an I
2 statistic of 75% and more indicates a considerable level of incon-
sistency (Higgins 2011). In the presence of considerable statistical
heterogeneity we used a random-effects model for pooling.
Assessment of reporting biases
If we had identified more than 10 RCTs, we planned to use funnel
plots to assess for the potential existence of small study bias. There
are a number of explanations for the asymmetry of a funnel plot
(Sterne 2001) and we planned to carefully interpret results (Lau
2006).
Data synthesis
We summarised data statistically if they were available, sufficiently
similar and of sufficient quality. We performed statistical analyses
according to the statistical guidelines referenced in the newest ver-
sion of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011).
The table of comparisons was divided into all possible outcomes
(e.g. all-cause mortality, disease specific death). It was not possible
to subdivide into different dosages within the outcome subgroups
as these data were not available.
Subgroup analysis and investigation of heterogeneity
No further subgroup analyses were performed.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore the
influence of the following factors on the effect estimates.
• Restricting the analysis to published studies.
• Restricting the analysis taking account of risk of bias, as
specified above.
• Restricting the analysis to very long or large studies in order
to establish how much they dominated the results.
• Restricting the analysis to studies using the following filters:
diagnostic criteria, language of publication, source of funding
(industry versus other), country.
We planned to test the robustness of the results by repeating the
analysis using different measures of effect estimates (relative risk,
odds ratio etc.) and different statistical models (fixed-effect and
random-effects models).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
For details see Characteristics of included studies; Characteristics
of excluded studies and Characteristics of ongoing studies.
Results of the search
Our search identified a total of 3281 references.We excluded 2477
references because they were on a different topic, 42 were con-
ducted on healthy volunteers or animals and 381 were not ran-
domised controlled trials. A further 198 studies were excluded as
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they used non-clinical outcomes, eight used intravenous medica-
tions and 91 used non-eligible populations, controls or interven-
tions. The remaining 84 abstracts were reviewed for duplication
and 29 separate trials were identified. We obtained full text pa-
pers for these 29 trials. Of these, 20 were excluded (11 because
the follow-up was less than 12 months, five did not have eligible
controls, two did not collect information about diabetes status,
one was observational and one excluded patients on insulin). One
ongoing trial was identified (SPS3 2011) leaving eight included
studies. There were 35 references identified in the search referring
to these eight included studies. For details please see Figure 1.
Included studies
We identified a total of eight completed randomised trials which
met the inclusion criteria (AAASPS 2003; CAPRIE 1996; CATS
1988; CHARISMA 2002; CURE 1998; Park 2010; PRoFESS
2008; TASS 1989). The oldest study was completed in 1988 (
CATS 1988) and the most recent study was completed in 2010
(Park 2010). A total of 21,379 patients with diabetes participated
in the eight studies. The mean duration of follow-up was 913 days
(range 365 days to 2373 days).
Three of the included studies investigated ticlopidine (AAASPS
2003; CATS 1988; TASS 1989). Ticlopidine was compared to as-
pirin in two trials: AAASPS 2003 which included African Amer-
ican participants with a recent history of stroke, and TASS 1989
which included patients with a neurological deficit. The third
study (CATS 1988) compared ticlopidine to placebo in patients
with a thromboembolic stroke.
Five included studies investigated clopidogrel. One study com-
pared clopidogrel to aspirin in 3866 diabetes patients with is-
chaemic stroke, myocardial infarction or peripheral arterial disease
(CAPRIE 1996). The PRoFESS 2008 study compared clopido-
grel to aspirin and dipyridamole in 20,332 patients with ischaemic
stroke, of which 5473 patients had diabetes. The remaining three
studies compared clopidogrel and aspirin to aspirin alone in a total
of 10,099 patients with diabetes; of whom 6555 patients hadmul-
tiple risk factors for coronary artery disease (CHARISMA 2002),
2840 patients had unstable angina (CURE 1998) and 704 patients
had undergone insertion of drug eluding stents 12 months prior
(Park 2010).
All trials investigating clopidogrel used a dose of 75 mg daily and
all ticlopidine trials used a dose of 250 mg twice daily. The dose of
aspirin ranged from 75 mg daily to 650 mg twice daily. All trials
recorded all-cause mortality, vascular mortality, myocardial infarc-
tion and stroke except two (Park 2010; PRoFESS 2008). Only
three trials contributed to the main primary outcome as diabetes
data were not available for the other five trials. See Characteristics
of included studies for details of each trial.
The CAPRIE 1996 trial classified patients as having diabetes if
defined as such by the investigator. No other studies provided
informationonhow the diagnosis of diabeteswasmade for patients
classified with diabetes.
Excluded studies
The full text of 21 potential studies was reviewed and excluded
from this study. Further information is available in Characteristics
of excluded studies and Characteristics of ongoing studies.
Risk of bias in included studies
The risk of bias assessment is demonstrated in Figure 2 and Figure
3.
Random sequence generation (selection bias)
All included studies used and reported an appropriate method of
randomisation, most commonly computer generated randomisa-
tion.
Allocation
Seven of the eight trials used and reported appropriate methods
of allocation concealment. Park 2010 was an open label trial with
study participants and investigators aware of the treatment assign-
ments.
Blinding
All of the included trials were double-blinded, except for the Park
2010 trial in which patients were asked at every visit which med-
ication they were taking. Outcomes were assessed as per standard
criteria; however, the assessors knew which medication patients
were taking and thus outcome assessment was not blinded either.
Incomplete outcome data
The number of participants lost to follow-up in the CHARISMA
trial was not reported (CHARISMA 2002). All other trials re-
ported their loss to follow-up rate. There was a similar withdrawal
rate - approximately 20% - in three trials (AAASPS 2003; CAPRIE
1996; CHARISMA 2002). The withdrawal rate of Park 2010 was
not clearly reported, although it appeared to be over half of the
patients. The withdrawal rate in CURE 1998 was also very high
(approximately 45%).
Selective reporting
The five most recent trials have available published protocols or
registered trial documents. The oldest three trials (CAPRIE 1996;
CATS 1988; TASS 1989), do not have previously published pro-
tocols with outcomes and so risk of selective reporting is unknown.
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Other potential sources of bias
All trials except Park 2010 received funding from the pharmaceu-
tical companies who developed and sold adenosine-diphosphate
(ADP) receptor antagonists. The role of the pharmaceutical fund-
ing for the AAASPS 2003 trial was reported to be limited to sup-
plying medications only.
Effects of interventions
See: Summary of findings for the main comparison
Unpublished data were sought from all trials, however, additional
unpublished information was only provided by the CATS trial.
The results presented are derived from data extracted from three
trials (CATS 1988; PRoFESS 2008; TASS 1989) including un-
published data provided for the CATS trial. No specific data on
patients with diabetes were available for any of the other trials. For
details see Appendix 3.
Primary outcomes
Mortality
All-cause mortality and vascular mortality data were only available
for one trial (CATS 1988). This trial included 335 patients with
diabetes (1.5% of the total diabetes participants included in this
review). In this trial, when compared to placebo, ticlopidine was
noted to have no significant effect on all-cause mortality (30/172
(17.4%) versus 23/163 (14.1%); OR 1.29 (95% CI 0.71 to 2.32)
(Analysis 1.1) or vascular mortality (18/172 (10.5%) versus 18/
163 (11%); OR 0.94 (95% CI 0.47 to 1.88) (Analysis 2.1).
Cardiovascular events
Fatal and non-fatal myocardial infarction
Data for combined fatal and non-fatal myocardial infarction were
only available for one trial (CATS 1988). Ticlopidine was not
noted to have any statistically significant effect on reducing this
outcome when compared to placebo (16/172 (9.3%) versus 19/
163 (11.7%); OR 0.78 (95% CI 0.39 to 1.57) (Analysis 4.1).
Fatal and non-fatal stroke
Data for the outcome fatal or non-fatal stroke were available from
two trials (30%of the total diabetes participants), comparing ADP
receptor antagonistswith other antiplatelet drugs (PRoFESS 2008;
TASS 1989). These two trials were statistically heterogeneous (I2
= 81%) and a random-effects model was used for pooling. Over-
all, in the pooled analysis there was no statistically significant re-
duction in the combination of fatal and non-fatal stroke ((359/
3194 (11.2%) versus 356/3146 (11.3%); OR 0.81 (95% CI 0.44
to 1.49)) for ADP receptor antagonists versus other antiplatelet
drugs (Analysis 3.4). In the study comparing ticlopidine with as-
pirin (TASS 1989) a reduction in fatal and non-fatal stroke was
demonstrated with the use of ticlopidine (25/291 (0.9%) versus
44/306 (0.14%) for aspirin; OR 0.56 (95% CI 0.33 to 0.94)
(Analysis 3.2). There was no significant reduction in fatal and non-
fatal strokes in diabetes patients when clopidogrel was compared
to aspirin combined with dipyramidole (334/2840 (0.12%) versus
312/2903 (0.11%); OR 1.12 (95% CI 0.05 to 1.32)) (PRoFESS
2008; Analysis 3.3).
Peripheral vascular disease
No data were available from any of the trials on the reduction of
peripheral vascular disease.
Secondary outcomes
Published or unpublished data on safety and adverse events,
health-related quality of life specifically for patients with diabetes
and costs were not available for any of the trials.
D I S C U S S I O N
This systematic review summarises the available data from eight
eligible studies on the effect of adenosine-diphosphate (ADP) re-
ceptor antagonists on mortality and cardiovascular disease in pa-
tients with diabetes.
Summary of main results
Available data did not demonstrate a significant benefit of ADP
receptor antagonists over placebo or other antiplatelet drugs in
reducing all-cause mortality, vascular mortality, stroke or myocar-
dial infarction. Ticlopidine was demonstrated to reduce combined
fatal and non-fatal strokes when compared to aspirin in one trial
(Analysis 3.2).
Overall completeness and applicability of
evidence
For most studies, data for patients with diabetes were incomplete.
Although eight trials comparing ADP receptor antagonists with
other antiplatelet drugs or placebo were eligible for inclusion,
only three provided data on patients with diabetes (CATS 1988;
PRoFESS 2008; TASS 1989) and only one CATS 1988 provided
data on more than one outcome for patients with diabetes. Au-
thors of all eight trials were contacted, one author provided infor-
mation (CATS 1988), the author of one study declined to provide
information (AAASPS 2003), one author did not have any further
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data (PRoFESS 2008) and the authors of the five remaining stud-
ies did not respond to two requests (CAPRIE 1996; CHARISMA
2002; CURE 1998; Park 2010; TASS 1989).
All trials reported on safety and adverse outcomes for all included
patients; however, none of the trials reported on adverse outcomes
for patients with diabetes separately. For all patients, all four trials
comparing ADP receptor antagonists with aspirin noted slightly
lower bleeding rates for clopidogrel and ticlopidine compared to
aspirin or aspirin and dipyridamole in combination (AAASPS
2003; CAPRIE 1996; PRoFESS 2008; TASS 1989). However,
these trials used higher doses of aspirin than are commonly pre-
scribed today. The trial comparing ticlopidine to placebo noted
one serious bleeding event in the placebo group comparedwith two
serious bleeding events in the ticlopidine group (CATS 1988). The
three trials which compared dual aspirin and clopidogrel therapy
to aspirin alone all noted increased bleeding risk with dual ther-
apy (CHARISMA 2002; CURE 1998; Park 2010). A Cochrane
review comparing dual therapy of clopidogrel and aspirin to as-
pirin alone noted there would be an additional six major bleeds
per 1000 people treated (Squizzato 2011).
None of the included trials reviewed peripheral vascular disease as a
cardiovascular endpoint. No trial used standard diagnostic criteria
to diagnose diabetes and none of the trials separated patients into
type 1 or type 2 diabetes.
There are no trials specifically designed to look at the efficacy
and safety of ADP receptor antagonists for patients with type 2
diabetes. Patients with diabetes have different metabolism and
platelet function to patients without diabetes which predisposes
them to cardiovascular disease (Angiolillo 2009) and this may
change the efficacy and safety of ADP receptor antagonists.
The use of ADP receptor antagonists in diabetes patients is based
on evidence for their use from the analysis of patients with and
without diabetes. Many major guidelines now recommend the
use of clopidogrel in certain situations. For example, the National
Institute of Health and Clinical Excellence guidelines recommend
clopidogrel for 12 months in all patients with unstable angina or
non-ST elevatedmyocardial infarction with a six month mortality
risk of greater than 1.5% (NICE 2010), based on the CURE
trial findings. As a result, many patients with diabetes are being
prescribed ADP receptor antagonists and newer ADP receptor
antagonists are now compared to clopidogrel rather than to other
antiplatelet agents despite there being limited evidence for patients
with diabetes.
The intention of this review was to assess the use of ADP receptor
antagonists in primary and secondary prevention. However, all of
the trials except one (CHARISMA 2002) enrolled patients who
had previous cardiovascular or cerebrovascular events. ADP recep-
tor antagonists in primary prevention of cardiovascular disease in
high risk vascular patients was investigated by the CHARISMA
trial, however, outcome data for patients with diabetes were un-
available from this trial.
Quality of the evidence
Overall the methodological quality of the eight included trials
was high. All of the trials except one (Park 2010) were double-
blind. The majority of the studies were funded by pharmaceutical
companies.
Most studies reported composite end points as well as individ-
ual outcome events. A specific analysis of diabetes patients of the
CAPRIE 1996 trial only reported a composite end point of vascu-
lar death, myocardial infarction, stroke and rehospitalisation for
bleeding or ischaemia (Bhatt 2002). From a clinical perspective,
reporting of composite endpoints is less useful as clinicians are
unable to provide relevant information to patients, for example,
the patient’s risk of death.
Potential biases in the review process
It is possible that we have missed trials through the search strategy
despite three databases being searched and relevant review articles
being handsearched. Of the included trials, unpublished diabetes-
specific data were provided by only one trial and this may have
introduced bias into the review.
Agreements and disagreements with other
studies or reviews
The largest meta-analysis of antiplatelet therapy versus con-
trol was done by the Antithrombotic Trialists Collaboration
(Antithrombotic Trialists’ Collaboration 2002). This meta-analy-
sis reviewed all antiplatelet agents including aspirin and failed to
show a statistically significant reduction in risk of serious vascular
events in patients with diabetes.
There are two Cochrane reviews on ADP receptor antagonists
which differ fromour review as they are not limited to patientswith
diabetes. One review included all patients with previous clinical
manifestations of atherosclerosis of the cerebral, coronary or pe-
ripheral circulation and assessed the composite end point of stroke,
myocardial infarction or vascular death. This review noted that
ADP receptor antagonists modestly reduced the odds of a serious
vascular event when compared to aspirin. The result just reached
statistical significance (11.6% versus 12.5%, OR 0.92 (0.85 to
0.99)) and the authors concluded that ADP receptor antagonists
were at least as effective as aspirin, possiblymore so (Sudlow 2009).
A different Cochrane review of clopidogrel and aspirin versus as-
pirin alone included all patients with known cardiovascular disease
or at high risk of atherothrombotic disease. The authors concluded
that in patients with acute non-ST coronary syndromes the ben-
efits of clopidogrel plus aspirin outweighed the harms (Squizzato
2011).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The role of adenosine diphosphate (ADP) receptor antagonists
in patients with diabetes is unclear. The use of ADP receptors
for prevention of cardiovascular disease in patients with diabetes
needs to be guided by evidence available from analysis done on
all patients, including those with and without diabetes. Current
available evidence analysed in previous Cochrane reviews suggests
ADP receptor antagonists were at least as effective as aspirin, pos-
sibly more so in preventing cardiovascular disease in secondary
prevention (Sudlow 2009) and that in acute non-ST coronary
syndromes the benefits of clopidogrel and aspirin outweighed the
harms (Squizzato 2011). Another factor to take into account is
the cost of ADP receptor antagonists which in many countries is
significantly higher than aspirin.
Implications for research
All future trials should separately report outcome data for patients
with diabetes to allow for development of clinical guidelines for
this specific patient population. Any previously conducted trial
should make diabetes specific data available for analysis regard-
less of outcomes. Improved identification and thorough analysis
of subgroups of diabetes patients in large primary and secondary
prevention trials would provide a more solid evidence base for rec-
ommendations for primary and secondary prevention in diabetes
patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AAASPS 2003
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
African American
29 to 85 years of age
Non-cardioembolic cerebral infarct
Cerebral infarct 7 to 90 days prior
CT or MRI consistent with occurrence of entry cerebral infarct (shows entry infarct, old
infarct, or no infarct)
Measurable neurological deficit that correlates with onset of entry cerebral infarct
Able to follow an outpatient treatment program
EXCLUSION CRITERIA:
Transient ischaemic attack
Subarachnoid haemorrhage
Cardiac embolism
Iatrogenic stroke
Postoperative stroke within 30 days of operation
Carotid endarterectomy as preventive treatment of entry cerebral infarct
Mean arterial blood pressure > 130 mm Hg on 3 consecutive days
Modified Barthel Index < 10
History of dementia or neurodegenerative disease
Severe comorbid condition such as cancer that would limit survival during 2-year follow-
up period
Concurrent enrolment in another clinical trial
Sensitivity or allergy to aspirin or ticlopidine
Women of childbearing potential
Peptic ulcer disease, active bleeding diathesis, lower gastrointestinal bleeding, platelet or
other haematologic abnormality clinically active in the past year
Haematuria
Positive stool guaiac
Prolonged prothrombin time or partial thromboplastin time
Blood urea nitrogen > 40 mg %,
Serum creatinine > 2.0 mg %
Thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet
count or white blood cell count
≥ 2 times the upper range of normal on liver function tests
PARTICIPANTS:
Total participants: 1809 (Aspirin: 907, Ticlodipine: 902)
Diabetes participants: 738 (Aspirin: 379, Ticlodipine: 359)
Total participants withdrawn or prematurely discontinuing study medication: 454 (As-
pirin: 215, Ticlodipine: 239)
Total participants lost to follow-up: 68 (Aspirin: 31, Ticlodipine: 37)
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AAASPS 2003 (Continued)
Interventions INTERVENTION: Ticlopidine 250 mg twice daily and placebo
CONTROL: Aspirin 325 mg twice daily and placebo
NUMBER OF STUDY CENTRES: 62
COUNTRY/ LOCATION: United States of America
SETTING: Hospital and community
Outcomes OUTCOMES (as documented in the published protocol):
Composite endpoint of myocardial infarction, recurrent stroke and vascular death
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Aspirin: 40, Ticlopidine: 45
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: Aspirin:18, Ticlopidine: 18
Myocardial infarction patients with diabetes (fatal): unknown
Myocardial infarction patients with diabetes (non-fatal): unknown
Myocardial infarction all patients (fatal): Aspirin: 0, Ticlopidine: 1
Myocardial infarction all patients (non-fatal): Aspirin: 8, Ticlopidine: 8
Stroke patients with diabetes (fatal): unknown
Stroke patients with diabetes (non-fatal): unknown
Stroke all patients (fatal): Aspirin: 2, Ticlopidine: 4
Stroke all patients (non-fatal): Aspirin: 84, Ticlopidine: 102
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients: Aspirin: 262, Ticlopidine: 270
Study details RUN-IN PERIOD: None
STUDY TERMINATED BEFORE REGULAR END: Yes - at 6.5 years
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “the primary hypothesis of this ... trial ... is that ticlopidine hydrochloride is more effec-
tive than aspirin in preventing the composite endpoints of recurrent stroke, myocardial
infarction, and vascular death among middle-aged and elderly African Americans with
non-cardioembolic ischemic stroke”
Notes Supported by the National Institute of Neurological Disorders and Stroke. Medications
and placebos were supplied by Roche Laboratories and Bayer
Abbreviations: CT: computed tomography; MRI: magnetic resonance imaging
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation algorithm developed by
chief study statistician”
Allocation concealment (selection bias) Low risk “Local site personnel call the Automated
Phone Registration System for AAASPS
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AAASPS 2003 (Continued)
operated by the Moffitt Cancer Research
Institute of the University of South Florida
... for allocation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “all study personnel were masked (blinded)
from treatment assignment with the excep-
tion of 1 study statistician who developed
the randomization algorithm”
“placebo tablets had identical physical
properties”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 276 participants withdrew in the Ticlopi-
dine group and 246 in the Aspirin group.
Analysis was done on intention-to-treat ba-
sis
Selective reporting (reporting bias) Low risk Outcomes reported as stated in the pub-
lished protocol
Other bias Low risk “Roche Laboratories and Bayer had no role
beyond supplying study medications and
placebos.”
CAPRIE 1996
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
Ischaemic stroke: (including retinal and lacunar infarction) ≥ 1 week and ≤ 6 months
and neurological signs persisting ≥ 1 week from stroke onset and CT or MRI ruling out
haemorrhage or non-relevant disease
MI: Onset ≤ 35 days before randomisation and two of:
Characteristic ischaemic pain for ≥ 20 min
Elevation of CK, CK-MB, LDH, or AST to 2 times upper limit of laboratory normal
with no other explanation
Development of new≥ 40 Q waves in at least two adjacent ECG leads or new dominant
R wave in V1 (R ≥ 1 mm > S in V1)
Atherosclerotic peripheral arterial disease: Intermittent claudication (WHO: leg pain on
walking, disappearing in < 10 min on standing) of presumed atherosclerotic origin; and
ankle/arm systolic BP ratio≤ 0·85 in either leg at rest (two assessments on separate days)
; or history of intermittent claudication with previous leg amputation, reconstructive
surgery, or angioplasty with no persisting complications from intervention
EXCLUSION CRITERIA:
Age < 21 years
Severe cerebral deficit likely to lead to patient being bedridden or demented
Carotid endarterectomy after qualifying stroke
Qualifying stroke induced by carotid endarterectomy or angiography
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CAPRIE 1996 (Continued)
Patient unlikely to be discharged alive after qualifying event
Severe comorbidity likely to limit patient’s life expectancy to less than 3 years
Uncontrolled hypertension
Scheduled for major surgery
Contraindications to study drugs
Severe renal or hepatic insufficiency
Haemostatic disorder or systemic bleeding
History of haemostatic disorder or systemic bleeding
History of thrombocytopenia or neutropenia
History of drug-induced haematologic or hepatic abnormalities
Known to have abnormal WBC, differential, or platelet count
Anticipated requirement for long-term anticoagulants, non-study antiplatelet drugs or
NSAIDs affecting platelet function
History of aspirin sensitivity
Women of childbearing age not using reliable contraception
Currently receiving investigation drug
Previously entered in other clopidogrel studies
Geographic or other factors making study participation impractical
CO-MEDICATIONS:
Antiplatelet or anticoagulation drugs were discontinued before randomisation. Patients
with anticipated need for long term anticoagulation or NSAIDs were excluded. Con-
comitant medications were recorded
PARTICIPANTS:
Total participants: 19,185 (Aspirin: 9546, Clopidogrel: 9553) [86 did not receive med-
ication, Aspirin 40, Clopidogrel 46]
Diabetes participants: 3866 (Aspirin: 20% of total group, Clopidogrel: 20% of total
group)
Total participants withdrawn or prematurely discontinuing study medication: 4059 (As-
pirin: 21.1%, Clopidogrel: 21.3%)
Total participants lost to follow-up: 42 (Aspirin: 20, Clopidogrel: 22)
Interventions INTERVENTION: Clopidogrel 75 mg daily and placebo
CONTROL: Aspirin 325 mg daily and placebo
NUMBER OF STUDY CENTRES: 384 centres
COUNTRY/ LOCATION: 16 countries
SETTING: Hospital and community
Outcomes OUTCOMES (as stated in the publication):
Non-fatal Ischaemic Stroke: acute neurological event with focal signs for≥ 24 hrs; if new
location without evidence of intracranial haemorrhage; if worsening of previous event,
must have lasted > 1 week, or more than 24 hrs if accompanied by appropriate CT or
MRI findings
Non-fatal MI: same as inclusion criteria
Non-fatal primary intracranial haemorrhage: Intracerebral haemorrhage (including in-
tracranial and subarachnoid), and subdural haematoma documented by appropriate neu-
roimaging investigations
Non-fatal leg amputation: Only if above the ankle and not done for trauma or cancer.
Fatal events: Ischaemic stroke (within 28 days of onset of symptoms/signs), MI (within
28 days of onset of symptoms signs), haemorrhage, other vascular causes (deaths that
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CAPRIE 1996 (Continued)
were not clearly non-vascular and did not meet other criteria) or non-vascular causes
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Aspirin: 571, Clopidogrel: 560
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: Aspirin: 378, Clopidogrel: 350
Myocardial infarction patients with diabetes (fatal): unknown
Myocardial infarction patients with diabetes (non-fatal): unknown
Myocardial infarction all patients (fatal): Aspirin: 75, Clopidogrel: 53
Myocardial infarction all patients (non-fatal): Aspirin: 301, Clopidogrel: 255
Stroke patients with diabetes (fatal): unknown
Stroke patients with diabetes (non-fatal): unknown
Stroke all patients (fatal): Aspirin: 42, Clopidogrel: 37
Stroke all patients (non-fatal): Aspirin: 504, Clopidogrel: 472
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients: Aspirin: 409, Clopidogrel: 360
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No (recruitment completed
early but follow-up remained at one year post recruitment completion)
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “to assess the potential benefit of clopidogrel, compared with aspirin, in reducing the
risk of ischaemic stroke, myocardial infarction, or vascular death in patients with recent
ischaemic stroke, recent myocardial infarction or peripheral arterial disease”
Notes This study was funded by Sanofi and Bristol-Myers Squibb
Abbreviations: AST aspartate aminotransferase; BP: blood pressure; CK: creatine ki-
nase; CK-MB: creatine kinase myocardial band; CT: computed tomography; ECG: elec-
trocardiogram; LDH: lactate dehydrogenase; MI: myocardial infarction; MRI: magnetic
resonance imaging; WBC: white blood cells; WHO: World Health Organisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The Independent Statistical Centre pro-
vided computer-generated .... with random
allocation”
Allocation concealment (selection bias) Low risk “The Independent Statistical Centre pro-
vided computer-generated .... with random
allocation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “These [Medication] supplies were in the
form of blister packs containing either
75 mg tablets of clopidogrel plus aspirin
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CAPRIE 1996 (Continued)
placebo tablets or 325 mg aspirin tablets
plus clopidogrel placebo tablets, such blis-
ter packs being indistinguishable from one
another ”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “19,185 patients ... were randomised”; “46
patients in clopidogrel group and 40 in as-
pirin group never took any study drug”;
“42 patients lost to follow-up ... included
in the analysis”
“4059 patients discontinued study drug
early...., 21.3% in clopidogrel and 21.1%
in the aspirin group. Reasons for stopping
study drug early were similar in the two
groups”
Comment: equal loss in both groups, in-
cluded in analysis.
Selective reporting (reporting bias) Unclear risk Registration of trial or prior protocol pub-
lication unavailable. Outcomes stated in
publication document reported
Other bias High risk “This study was funded by Sanofi and Bris-
tol-Myers Squibb”
CATS 1988
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
Thromboemoblic stroke 1 week to 4 months prior to entry into study
Diagnosis based on clinical assessment and history
Neurological deficit had to be persistent at time of entry into study
CT scan excluded haemorrhagic stroke or other intracerebral pathology
EXCLUSION CRITERIA:
Cardioembolic strokes (defined as two of AF, sick sinus syndrome, seizure at onset,
involvement in more than one vascular territory)
Bedridden or dementia
Life-limiting illness
Contraindications to ticlopidine (hepatic or renal insufficiency, haemostatic disorder,
thrombocytopenia, history of drug-induced haematologic abnormalities)
Significant laboratory test abnormalities
Carotid endarterectomy prior to randomisation
Stroke due to carotid endarterectomy
Long term anticoagulation or antiplatelet therapy required
History of drug or alcohol abuse
Inclusion in another trial
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CATS 1988 (Continued)
PARTICIPANTS:
Total participants: 1053 (Ticlodipine: 525, Placebo: 528)
Diabetes participants: 335 (Ticlodipine: 172, Placebo: 163)
Total participants withdrawn or prematurely discontinuing study medication: 402
(Ticlodipine: 238, Placebo: 164)
Total participants lost to follow-up: 4 (Ticlodipine: 3, Placebo: 1)
Interventions INTERVENTION: Ticlopidine 250 mg twice daily
CONTROL: Placebo
NUMBER OF STUDY CENTRES: 25
COUNTRY/ LOCATION: USA and Canada
SETTING: Hospital inpatient
Outcomes OUTCOMES (as reported in published protocol):
Non-fatal stroke:
Diagnosis based on clinical assessment and history
Duration of > 24 hours if in new location or > 1 week if worsening of previous deficit
unless accompanied by new CT finding
CT scan excluded haemorrhagic stroke or other intracerebral pathology
Non-fatal myocardial infarction:
At least two of:
a) typical symptoms of pain
b) compatible ECG changes or positive pyrophosphate radionuclide scan
c) appropriate serum enzyme changes (peak value > twice upper limit of normal)
Vascular death:
New cerebral infarction
Myocardial infarction
Sudden death
Congestive heart failure
All cause mortality patients with diabetes: 30 ticlopidine, 23 placebo
All cause mortality all patients: 66 ticlopidine, 65 placebo
Vascular mortality patients with diabetes with diabetes: 18 ticlopidine, 18 placebo
Vascular mortality all patients: 35 ticlopidine, 43 placebo
Myocardial infarction patients with diabetes (fatal): 13 ticlopidine, 10 placebo
Myocardial infarction patients with diabetes (non-fatal): 3 ticlopidine, 9 placebo
Myocardial infarction all patients (fatal): 21 ticlopidine, 22 placebo
Myocardial infarction all patients (non-fatal): 11 ticlopidine, 15 placebo
Stroke patients with diabetes (fatal): 6 ticlopidine, 9 placebo
Stroke patients with diabetes (non-fatal): 28 ticlopidine, 32 placebo
Stroke all patients (fatal): 14 ticlopidine, 17 placebo
Stroke all patients (non-fatal): 67 ticlopidine, 86 placebo
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients: 43 ticlopidine, 15 placebo
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
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CATS 1988 (Continued)
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “to assess the effect of ticlopidine (250 mg twice daily) in reducing the rate of subsequent
occurrence of stroke, myocardial infarction, or vascular death in patients who have had
a recent thromboembolic stroke”
Notes This study was funded by Syntax Research (USA) Inc and Sanofi, France
Abbreviations: AF: atrial fibrillation; CT: computed tomography; ECG: electrocardio-
gram
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Prescribed randomisation arrangement
generated separately for each clinical cen-
tre, 528 patients randomised to placebo,
525 to ticlopidine
Allocation concealment (selection bias) Low risk Only the safety committee knew the ran-
domisation code for a particular centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk Ticlopidine was supplied.... in plastic con-
tainers .... placebo tablets were identical in
packaging and appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 patients lost to follow-up, 3 in ticlopidine
group, 1 in placebo group
Selective reporting (reporting bias) Unclear risk Registration of trial or prior protocol pub-
lication unavailable. Outcomes stated in
publication document reported
Other bias High risk Funded by pharmaceutical company
CHARISMA 2002
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
High risk primary prevention: 2 major risk factors or 3 minor risk factors or 1 major
and 2 minor risk factors
Major risk factors:
Diabetes mellitus (on drug therapy)
Diabetic neuropathy
ABI < 0.9
Asymptomatic carotid stenosis ≥ 70%
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CHARISMA 2002 (Continued)
Carotid plaque evidence by intima-media thickness
Minor risk factors:
Systolic BP ≥ 150 mm Hg despite therapy for 3 months
Primary hypercholesterolaemia
Current smoker > 15 cigarettes per day
Male ≥ 65 years, female ≥ 70 years
Coronary artery disease: 1 of:
Stable angina with document multivessel coronary disease
History of multivessel CABG
History of multivessel PCI
Previous MI
Cerebrovascular disease: previous ischaemic stroke or TIA
Peripheral arterial disease: intermittent claudication with ABI ≤ 0.85 or intermittent
claudication with previous intervention
EXCLUSION CRITERIA:
Chronic oral antithrombotic medications (warfarin, high dose aspirin, NSAIDs)
Requiring prolonged clopidogrel therapy
CO-MEDICATIONS:
Concurrent oral antithrombotic therapy not permitted. Other standard therapy at the
discretion of clinicians
PARTICIPANTS:
Total participants: 15,603 (Clopidogrel: 7802, Placebo: 7801)
Diabetes participants: 6556 (Clopidogrel: 3304, Placebo: 3252)
Total participants withdrawn or prematurely discontinuing study medication: Clopido-
grel: 20.4%, Placebo: 18.2%
Total participants lost to follow-up: unknown
Interventions INTERVENTION: Clopidogrel 75 mg daily and aspirin 75 mg to 162 mg daily
CONTROL: Placebo and aspirin 75 mg to 162 mg daily
NUMBER OF STUDY CENTRES: 768
COUNTRY/ LOCATION: 32 countries
SETTING: Hospital
Outcomes OUTCOMES (as stated in the published protocol):
Primary outcome: first occurrence of cardiovascular death, MI (according to American
College of Cardiology definition) or stroke (acute onset of focal neurological symptoms
or signs lasting more than 24 hours, with CT or MRI to exclude other causes)
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Clopidogrel: 371, Placebo: 374
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: Clopidogrel: 238, Placebo: 229
Myocardial infarction patients with diabetes (fatal): unknown
Myocardial infarction patients with diabetes (non-fatal): unknown
Myocardial infarction all patients (fatal): unknown
Myocardial infarction all patients (non-fatal): Clopidogrel: 146, Placebo: 155
Stroke patients with diabetes (fatal): unknown
Stroke patients with diabetes (non-fatal): unknown
Stroke all patients (fatal): unknown
Stroke all patients (non-fatal): Clopidogrel: 150, Placebo: 189
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CHARISMA 2002 (Continued)
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients (only bleeding recorded): Clopidogrel: 130, Placebo:
104
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL & NON-COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study To test if “clopidogrel in combinationwith aspirin would be an improvement over aspirin
alone across the spectrum of high risk patients with atherothrombosis”
Notes Sponsored and funded by Sanofi-Aventis and Bristol-Myers Squibb and the National
Institutes of Health
Abbreviations: ABI: ankle brachial index; CABG: coronary artery bypass grafting; CT:
computed tomography; MI: myocardial infarction; MRI: magnetic resonance imaging;
NSAIDs: non-steriodal anti-inflammatory drugs; PCI: percutaneous coronary interven-
tion; TIA: transient ischaemic attack
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “pre-established randomisation scheme,
stratified according to site”
Allocation concealment (selection bias) Low risk “Study drug assignment was performed
centrally by an interactive voice-response
system”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Matching placebo drug”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rate 20% for clopidogrel
group, 18.2% for placebo group. Number
of patients lost to follow-up unknown
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias High risk Pharmaceutical funding fromSanofi-Aven-
tis and Bristol-Myers Squibb
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CURE 1998
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
Admitted to hospital with:
Symptoms suggestive of ACS without ST segment elevation > 1 mm
Within 24 hours of onset of chest pain/symptoms
Either ECG changes compatible with new ischaemia or elevated cardiac enzymes or
troponin I or T at least twice upper limit of normal
EXCLUSION CRITERIA:
Contraindications to antiplatelet/antithrombotic therapy
High risk of bleeding
Class IV heart failure
Ongoing long term need for anticoagulants
PTCA/stent or CABG within 3 months prior to randomisation
CO-MEDICATIONS:
Aspirin (75 mg to 325 mg) started at randomisation or continued if already taking
PARTICIPANTS:
Total participants: 12,562 (Clopidogrel: 6259, Placebo: 6303)
Diabetes participants: 2840 (Clopidogrel: 1405, Placebo: 1435)
Total participants withdrawn or prematurely discontinuing study medication: Clopido-
grel: 21.1%, Placebo: 18.8%
Total participants lost to follow-up: 13 (Clopidogrel: 6, Placebo: 7)
Interventions INTERVENTION: 300 mg loading dose of clopidogrel then 75 mg per day and aspirin
75 mg to 325 mg daily
CONTROL: Placebo and aspirin 75 mg to 325 mg daily
NUMBER OF STUDY CENTRES: 482
COUNTRY/ LOCATION: 28 countries
SETTING: Hospital
Outcomes OUTCOMES (as stated in the published protocol):
1. The composite of cardiovascular death, non-fatal myocardial infarction or stroke
2. The composite of cardiovascular death, non-fatal myocardial infarction, stroke or
refractory ischaemia
Death from cardiovascular cause: death for which there was no clearly documented non-
vascular cause
Myocardial infarction: presence of at least two of: ischaemic chest pain, elevation of
cardiac markers or enzymes to at least twice upper limit of normal within 48 hours after
percutaneous coronary intervention (or to a level 20% higher than the previous value
if the level had already been elevated because of an early myocardial infarction), ECG
changes compatible with infarction
Stroke: result of intracranial haemorrhage, ischaemia or uncertain cause
Refractory ischaemia in hospital: recurrent chest pain lastingmore than fiveminutes with
new ischaemic ECG changes while the patient was receiving optimal medical therapy
(two anti-anginal agents, includingVnitrate unless contraindicated) leading to additional
intervention by midnight of the next calendar day
Refractory ischaemia on discharge: rehospitalisation lasting at least 24 hours for unstable
angina with ischaemic ECG changes
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CURE 1998 (Continued)
Severe ischaemia: Ischaemia similar to refractory ischaemia for which no urgent inter-
vention was performed
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Clopidogrel: 359, Placebo: 390
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: Clopidogrel: 318, Placebo: 345
Myocardial infarction patients with diabetes (fatal): unknown
Myocardial infarction patients with diabetes (non-fatal): unknown
Myocardial infarction all patients (fatal and non-fatal): Clopidogrel: 324, Placebo 419
Stroke patients with diabetes (fatal): unknown
Stroke patients with diabetes (non-fatal): unknown
Stroke all patients (fatal and non-fatal): Clopidogrel: 75, Placebo: 87
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients (only bleeding recorded): Clopidogrel: 231, Placebo:
169
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No - study initially designed
for 9000 patients, however, increased to 12,500 due to lower event rates than expected
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “To compare the efficacy and safety of the early and long-term use of clopidogrel plus
aspirin with those of aspirin alone in patients with acute coronary syndromes and no
ST-segment elevation”
Notes Supported by Sanofi-Synthelabo and Bristol-Myers Squibb
Abbreviations: ACS: acute coronary syndrome; ECG: electrocardiogram; PTCA: per-
cutaneous transluminal coronary angioplasty; CABG: coronary artery bypass grafting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomised to either clopidogrel or
placebo by telephone call to central com-
puterised randomisation service”
“Permuted block randomisation .... is used”
Allocation concealment (selection bias) Low risk “Telephone call to central computerised
randomisation service”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Blinded study drug... matching placebo”
“A central committee of clinicians who are
blinded to treatment allocation will adju-
dicate ... outcomes”
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CURE 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk “Vital status was ascertained for 12,549 of
the 12,562 patients who underwent ran-
domization (99.9 percent), with 6 patients
in the clopidogrel group and 7 in the
placebo group lost to follow-up”
“46.2% of patients in clopidogrel group
discontinued study medication ... as com-
pared with 45.4% in the placebo group”
Selective reporting (reporting bias) Low risk Outcome data reported as stated in pub-
lished protocol
Other bias High risk Funded by pharmaceutical company
Park 2010
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
Undergone implantation of drug eluting stents at least 12 months before enrolment
Receiving dual antiplatelet therapy at time of enrolment
EXCLUSION CRITERIA:
Major adverse cardiovascular event (myocardial infarction, stroke, repeat revascularisa-
tion) since implantation
Major bleeding since implantation
Contraindications to the use of antiplatelet drugs
Requirement of long term clopidogrel
Non-cardiac coexisting condition with anticipated life expectancy of less than one year
Participitation in another trial
CO-MEDICATIONS:
Usual care as per treating physician
PARTICIPANTS:
Total participants: 2701 (Clopidogrel and aspirin: 1357, Aspirin only: 1344)
Diabetes participants: 704 (Clopidogrel and aspirin: 340, Aspirin: 364)
Total participants withdrawn or prematurely discontinuing study medication: 2061
(Clopidogrel and aspirin: 1030, Aspirin: 1031)
Total participants lost to follow-up: unknown
Interventions INTERVENTION: Clopidogrel 75 mg daily and aspirin 100 mg to 200 mg daily
CONTROL: Aspirin 100 mg to 200 mg per day
NUMBER OF STUDY CENTRES: 22
COUNTRY/ LOCATION: South Korea
SETTING: Inpatient and community
TREATMENT BEFORE STUDY: Dual antiplatelet therapy
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Park 2010 (Continued)
Outcomes OUTCOMES (as stated in registered trial documents):
Myocardial infarction
Death from cardiac causes
Death from any cause
Composite of myocardial infarction, stoke, death from cardiac causes
Major bleeding
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Aspirin and clopidogrel: 20, Aspirin only 13
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: unknown
Myocardial infarction patients with diabetes (fatal and non-fatal): unknown
Myocardial infarction all patients (fatal and non-fatal): Aspirin and clopidogrel: 10,
Aspirin only: 7 [specific numbers for fatal and non-fatal unknown]
Stroke patients with diabetes (fatal and non-fatal): unknown
Stroke all patients (fatal and non-fatal): Aspirin and clopidogrel: 9, Aspirin only: 4
[specific numbers for fatal and non-fatal unknown]
Major bleeding patients with diabetes: unknown
Major bleeding all patients: Aspirin and clopidogrel: 3, Aspirin only: 1
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING: No
NON-COMMERCIAL FUNDING: Unknown
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “evaluated the effect of the use of dual antiplatelet therapy for more than 12 months
on long-term clinical outcomes in patients who had undergone initial PCI with the
placement of a drug-eluting stent”
Notes “Therewas no industry involvement in the design, conduct, financial support, or analysis”
Abbrevations: PCI: percutaneous coronary intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “assignments weremade according to a pre-
established, computer-generated random-
ization scheme, with stratification on the
basis of site and type of ... drug eluting
stent”
Allocation concealment (selection bias) High risk “the trial was open label study..... subjects
and the investigators were aware of the
treatment assignments”
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Blinding (performance bias and detection
bias)
All outcomes
High risk Participants and investigators were not
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk More than half of the patients discontinued
study medication by the end of the study
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias Low risk “no industry involvement in the design,
conduct, financial support, or analysis”
PRoFESS 2008
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
FACTORIAL RCT: 2 x 2 factorial design comparing aspirin and dipyridamole with
clopidogrel and telmisartan with placebo
Participants INCLUSION CRITERIA:
1. Patients ≥ 55 years AND ischaemic stroke within 90 days before randomisation
After enrolment of 6000 patients the protocol was amended to broaden the inclusion
criteria as follows:
2. Patients 50to 54 years AND ischaemic stroke within 120 days AND two additional
risk factors (diabetes mellitus, hypertension, smoker at time of qualifying stroke, obesity
(bodymass index >30), previous vascular disease (stroke,MIor peripheral arterial disease)
, end-organ damage (retinopathy, left ventricular hypertrophy or microalbuminuria) or
hyperlipidaemia
3. Patients ≥ 55 years AND ischaemic stroke within 120 days AND two additional risk
factors
EXCLUSION CRITERIA:
1. Patients unable to give informed consent
2. Patients presenting with a primary haemorrhagic stroke (intracerebral haemorrhage
or subarachnoid haemorrhage)
3. Patients who are unable to take by mouth all required study medication
4. Known brain tumour
5. Pre-stroke history of dementia requiring institutional care
6. A modified Rankin scale score > 4 at baseline
7. The patient is unlikely to be released from hospital following the qualifying stroke, or
the presence of a severe disability after the qualifying stroke likely to lead to the patient
being bedridden or demented, or a non-vascular disease or condition which makes it
unlikely that the patient will survive to the end of the trial
8. Patients whose qualifying stroke had been induced by a surgical or cardiovascular
procedure such as carotid endarterectomy, angiogram or cardiac surgery
9. Patients with known hypersensitivity to dipyridamole, clopidogrel, aspirin or telmis-
artan
10. Uncontrolled hypertensionwhich equals or exceeds either a sitting systolic BP greater
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than 180 mm Hg, or a sitting diastolic BP greater than 110 mm Hg (all hypertensive
patients are treated appropriately, and ‘goal’ BPs are much lower than 180/110)
11. Seated systolic BP ≤ 120 mm Hg for patients who are still hospitalised following
the qualifying stroke
12. Patients currently being treated with an angiotensin II receptor blocker who are
unable or unwilling to discontinue treatment with this type of drug
13. Patients with required or planned continued treatment with antithrombotics or
anticoagulants including heparin or warfarin, or non-study platelet inhibitors
14. Known severe renal insufficiency defined as renal artery stenosis or creatinine clear-
ance < 0.6 ml/s or serum creatinine > 265 µmol/L (> 3.0 mg/dL)
15. Known severe hepatic dysfunction as defined by the following laboratory parameters:
SGPT (ALT) or SGOT (AST) > 4 times upper limit of normal, or total bilirubin > 20
µmol/L
16. Hyperkalaemia, defined as potassium > 5.5 mmol/L
17. Uncorrected volume depletion or sodium depletion
18. Known current active peptic ulcer disease
19. Patients with the syndrome of asthma, rhinitis and nasal polyps (all three present)
20. Known severe coronary artery disease including unstable angina pectoris or an MI
within the previous 3 months
21. Patients considered unreliable by the investigator concerning the requirements for
follow-up during the study and/or compliance with study drug administration
22. Known presence of or history of a haemostatic disorder or systemic bleeding
23. History of thrombocytopenia (i.e. less than 100 × 109/L for platelets) or neutropenia
(1.2 × 109/L for neutrophils)
24. Women who are breast-feeding, pregnant or of childbearing potential who do not
use a medically acceptable form of contraception
25. Patients who have been exposed to an investigational drug or device within the last
30 days, or are currently participating in such a trial
26. Patients scheduled for major surgery, carotid endarterectomy or carotid angioplasty
shouldnot enter the study; such patientsmay enter the trial 4weeks after such procedures,
if they still meet all other entry criteria
PARTICIPANTS:
Total participants: 20,332 (Clopidogrel: 10,151, Aspirin/dipyridamole: 10,181)
Diabetes participants: 5743 (Clopidogrel: 2840, Aspirin/dipyridamole: 2903)
Total participants withdrawn or prematurely discontinuing study medication: Clopido-
grel: 2290, Aspirin/dipyridamole: 2961)
Total participants lost to follow-up: 250 (Clopidogrel: 125, Aspirin/dipyridamole: 125)
Interventions INTERVENTION: Clopidogrel 75 mg daily and placebo
CONTROL: Aspirin/dipyridamole 25 mg/200 mg twice daily and placebo
For the first 8 months, 2027 patients in the clopidogrel group were receiving aspirin and
clopidogrel however the MATCH trial demonstrated increased bleeding with aspirin and
clopidogrel so the protocol was changed to clopidogrel only.
NUMBER OF STUDY CENTRES: 695
COUNTRY/ LOCATION: 35 countries
SETTING: Hospital and community
Outcomes OUTCOMES (as stated in the published protocol):
Primary outcome event:
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PRoFESS 2008 (Continued)
Stroke (non-fatal or fatal) either ischaemic or haemorrhagic or of uncertain cause
Secondary outcome events:
Vascular events either stroke or MI or vascular death
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Clopidogrel: 756, Aspirin/dipyridamole: 739
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: unknown
Myocardial infarction patients with diabetes (fatal and non-fatal): unknown
Myocardial infarction all patients (fatal and non-fatal): Clopidogrel: 197, Aspirin/dipyri-
damole: 178 [specific numbers for fatal and non-fatal unknown]
Stroke patients with diabetes (fatal and non-fatal): Clopidogrel: 334, Aspirin/dipyri-
damole: 312 [specific numbers for fatal and non-fatal unknown]
Stroke all patients (fatal and non-fatal): Clopidogrel: 862, Aspirin/dipyridamole: 879
[specific numbers for fatal and non-fatal unknown]
Serious adverse event patients with diabetes: unknown
Serious adverse event all patients (only bleeding recorded): Clopidogrel: 365, Aspirin/
dipyridamole: 419
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “to compare the relative efficacy and safety of aspirin plus extended-release dipyridamole
with that of clopidogrel among patients who had a recent ischemic stroke”
Notes Supported by Boehringer Ingelheim (which manufactures Aggrenox [a combination of
extended-release dipyridamole and aspirin] and Micardis [telmisartan])
Abbreviations: BP: blood pressure; MI: myocardial infarction; SGOT (AST): Serum
glutamic oxaloacetic transaminase / aspartate transaminase;.SGPT (ALT): Serum glu-
tamic pyruvate transaminase / alanine transaminase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization to telmisartanwas
stratified based onwhether or not individu-
als were receivingACE inhibitors, although
the analysis will be based on both strata
combined. Patients were randomized using
a central telephone randomization system.
” (from protocol of PRoFESS)
Allocation concealment (selection bias) Low risk “Patients were randomized using a central
telephone randomization system”
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PRoFESS 2008 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “the medication was ‘double dummy’ ... so
that all patients received identically appear-
ing medication kits”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 175 patients lost in both groups
Selective reporting (reporting bias) Low risk Outcomes reported as stated
Other bias High risk “the ASA active and placebo component of
the clopidogrel arm was discontinued fol-
lowing the presentation of theMATCH re-
sults and removed from subsequent treat-
ment kits”
Funded by Boehringer Ingelheim
TASS 1989
Methods RANDOMISED CONTROLLED CLINICAL TRIAL, RANDOMISATION RA-
TIO: 1:1, EQUIVALENCE DESIGN
Participants INCLUSION CRITERIA:
One of the following within the past 3 months:
Transient Ischaemic attack: focal ischaemic cerebrovascular event lasting < 24 hours
followed by complete recovery
Amaurosis fugax: unilateral ischaemic retinal episode lasting < 24 hours
Reversible ischaemic neurologic deficit: focal ischaemic cerebrovascular event lasting >
24 hours and < 3 weeks followed by complete recovery
Minor stroke: focal ischaemic cerebrovascular event results in minimal permanent neu-
rologic deficit and at least 80% recovery of function within three weeks
EXCLUSION CRITERIA:
Carotid artery surgery within last three months
Moderate to major stroke within last three months
Women with child bearing potential
Cardiogenic embolism
Haematological disorders
History of peptic ulcer disease or gastrointestinal bleeding
Life-threatening diseases such as cancer
Hypersensitivity or intolerance to aspirin
Need for continued use of aspirin or anticoagulants
CONCURRENT MEDICATIONS: Anticoagulants and antiplatelets prohibited
PARTICIPANTS:
Total participants: 3069 (Ticlodipine: 1529, Aspirin: 1540) [12 participants later judged
ineligible]
Diabetes participants: 597 (Ticlodipine: 291, Aspirin: 306)
Total participants withdrawn or prematurely discontinuing study medication: 1216
(Ticlopidine: 655, Aspirin: 561)
Total participants lost to follow-up: 84 (Ticlodipine: 46, Aspirin: 38)
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Interventions INTERVENTION: Ticlopidine 250 mg twice daily
CONTROL: Aspirin 650 mg twice daily
NUMBER OF STUDY CENTRES: 56
COUNTRY/ LOCATION: United States and Canada
SETTING: Hospital and community
Outcomes OUTCOMES (as stated in the published report):
Stroke: Demonstration of brain infarction at autopsy or rapid onset of focal cerebral
dysfunction > 24 hours associated with typical findings on neurologic examination,
laboratory studies and radiologic tests
Death from all causes
All cause mortality patients with diabetes: unknown
All cause mortality all patients: Ticlopidine: 175, Aspirin: 196
Vascular mortality patients with diabetes: unknown
Vascular mortality all patients: Ticlopidine: 120, Aspirin: 116
Myocardial infarction patients with diabetes (fatal): unknown
Myocardial infarction patients with diabetes (non-fatal): unknown
Myocardial infarction all patients (fatal): Ticlopidine: 21, Aspirin: 14
Myocardial infarction all patients (non-fatal): unknown
Stroke patients with diabetes (fatal and non-fatal): Ticlopidine: 25, Aspirin: 44 [specific
numbers for fatal and non-fatal unknown]
Stroke all patients (fatal): Ticlopidine: 16, Aspirin: 23
Stroke all patients (non-fatal): Ticlopidine: 156, Aspirin:189
Serious adverse event patients with diabetes: unknown
Serious adverse event (bleeding only) all patients: Ticlopidine: 137, Aspirin: 152
Study details RUN-IN PERIOD: No
STUDY TERMINATED BEFORE REGULAR END: No
Publication details LANGUAGE OF PUBLICATION: English
COMMERCIAL FUNDING
PUBLICATION STATUS: PEER REVIEW JOURNAL
Stated aim of study “to test the usefulness of ticlopidine in preventing stroke or death in patients at high
risk, we undertook a randomized trial comparing ticlopidine and aspirin”
Notes “supported by Syntex Research, Palo Alto, Calif.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomization within each center strati-
fied on ... history of ischemic cardiovascu-
lar disease, the occurrence of a moderate or
major stroke more than three months be-
fore entry, and the patient’s sex” “Maryland
Medical Research Institute ... randomly as-
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signed eligible patients”
Allocation concealment (selection bias) Low risk “only the Maryland Medical Research In-
stitute and an independent, external safety
committee had access to the randomized
code”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “medications were suppIied in identical
capsules and containers”
“Blinded adjudicators ... classified alI end-
point events using standardized criteria
drawn up
before the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “intention to treat analyses were per-
formed”
less than 3% loss to follow-up
Selective reporting (reporting bias) Unclear risk Published protocol or registered trial doc-
ument not available
Other bias High risk Pharmaceutical funded
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balsano 1990 Follow-up only 6 months
CHANCE 2010 Follow-up only 3 months
CLARITY 2005 Follow-up only 30 days
COMMIT 2005 Follow-up only 30 days
CREDO 2002 Placebo group received clopidogrel for 30 days after PCI
Cun 2002 Follow-up only 6 months
Harrington 2009 Follow-up only 30 days
Ishikawa 1997 Observational trial
JUMBO TIMI 2005 Follow-up only 30 days
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Li 1999 Diabetes information not collected
Machraoui 2001 Follow-up only 3 months
MATCH 2004 ADP-receptor inhibitor was not compared with alternative treatment or placebo
Mueller 2003 Intervention for only 4 weeks
PLATO 2006 ADP-receptor inhibitor is not compared with alternative treatment or placebo
STAMI 2001 Follow-up only 3 months
STIMS 1990 Diabetes patients on insulin excluded
TISS 1997 Follow-up only 30 days
Tohgi 1987 Diabetes information not collected
TOPALS 2003 ADP-receptor inhibitor was not compared with alternative treatment or placebo
TRITON-TIMI 38 2008 ADP-receptor inhibitor was not compared with alternative treatment or placebo
Characteristics of ongoing studies [ordered by study ID]
SPS3 2011
Trial name or title Secondary Prevention of Small Subcortical Strokes (SPS3)
Methods Randomised controlled trial
Participants 3000 patients with small subcortical strokes within the last 6 months
Interventions Clopidogrel and aspirin or aspirin and placebo
Intensive or usual blood pressure treatment
Outcomes Recurrent stroke, rate of cognitive decline and major vascular events
Starting date February 2003
Contact information SPS3 Coordinating Centre
UBC Department of Medicine | Division of Neurology
S169-2211 Wesbrook Mall, Vancouver, BC, V6T 2B5
Phone: 604-822-1789
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. All-cause mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ticlopidine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Vascular mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ticlopidine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Stroke (fatal and non-fatal)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ticlodipine vs placebo 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Ticlodipine vs aspirin 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Clopidogrel vs aspirin &
dipyridamole
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4 ADP receptor antagonists vs
other antiplatelet drug
2 6340 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.44, 1.49]
Comparison 4. Myocardial infarction (fatal and non-fatal)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ticlopidine/Placebo 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 All-cause mortality, Outcome 1 Ticlopidine vs placebo.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 1 All-cause mortality
Outcome: 1 Ticlopidine vs placebo
Study or subgroup Ticlopidine Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATS 1988 30/172 23/163 1.29 [ 0.71, 2.32 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 30 (Ticlopidine), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ticlopidine Favours Placebo
Analysis 2.1. Comparison 2 Vascular mortality, Outcome 1 Ticlopidine vs placebo.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 2 Vascular mortality
Outcome: 1 Ticlopidine vs placebo
Study or subgroup Ticlopidine Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATS 1988 18/172 18/163 0.94 [ 0.47, 1.88 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 18 (Ticlopidine), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ticlopidine Favours Placebo
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Analysis 3.1. Comparison 3 Stroke (fatal and non-fatal), Outcome 1 Ticlodipine vs placebo.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 3 Stroke (fatal and non-fatal)
Outcome: 1 Ticlodipine vs placebo
Study or subgroup Ticlodipine Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATS 1988 34/172 41/163 0.73 [ 0.44, 1.23 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 34 (Ticlodipine), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Ticlopidine Favours Placebo
Analysis 3.2. Comparison 3 Stroke (fatal and non-fatal), Outcome 2 Ticlodipine vs aspirin.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 3 Stroke (fatal and non-fatal)
Outcome: 2 Ticlodipine vs aspirin
Study or subgroup Ticlopidine Aspirin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
TASS 1989 25/291 44/306 0.56 [ 0.33, 0.94 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 25 (Ticlopidine), 44 (Aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours ticlodipine Favours aspirin
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Analysis 3.3. Comparison 3 Stroke (fatal and non-fatal), Outcome 3 Clopidogrel vs aspirin & dipyridamole.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 3 Stroke (fatal and non-fatal)
Outcome: 3 Clopidogrel vs aspirin % dipyridamole
Study or subgroup Clopidogrel Aspirin/dipyridamole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PRoFESS 2008 334/2840 312/2930 1.12 [ 0.95, 1.32 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 334 (Clopidogrel), 312 (Aspirin/dipyridamole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Clopidogrel Favours Aspirin/dipyridam
Analysis 3.4. Comparison 3 Stroke (fatal and non-fatal), Outcome 4 ADP receptor antagonists vs other
antiplatelet drug.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 3 Stroke (fatal and non-fatal)
Outcome: 4 ADP receptor antagonists vs other antiplatelet drug
Study or subgroup
ADP
receptor
antagonists
Other
antiplatelet
drugs Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
PRoFESS 2008 334/2903 312/2840 57.9 % 1.05 [ 0.89, 1.24 ]
TASS 1989 25/291 44/306 42.1 % 0.56 [ 0.33, 0.94 ]
Total (95% CI) 3194 3146 100.0 % 0.81 [ 0.44, 1.49 ]
Total events: 359 (ADP receptor antagonists), 356 (Other antiplatelet drugs)
Heterogeneity: Tau2 = 0.16; Chi2 = 5.18, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours ADP Favours control
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Analysis 4.1. Comparison 4 Myocardial infarction (fatal and non-fatal), Outcome 1 Ticlopidine/Placebo.
Review: Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus
Comparison: 4 Myocardial infarction (fatal and non-fatal)
Outcome: 1 Ticlopidine/Placebo
Study or subgroup Ticlopidine Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CATS 1988 16/172 19/163 0.78 [ 0.39, 1.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 16 (Ticlopidine), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Ticlopidine Favours Placebo
A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Characteris-
tic
Study ID
Intervention
(s) and con-
trol(s)
[n] screened [n]
randomised
[n] ITT [n] finishing
study
[%] of ran-
domised par-
ticipants
finishing
study
AAASPS I(d): Ticlopi-
dine 250 mg
bd (diabetes
patients)
C(d): Aspirin
325 mg bd
(diabetes pa-
tients)
I(t)
I- I(d): 359
C(d): 379
I(t): 902
C(t): 907
I(d): 359
C(d): 379
I(t): 902
C(t): 907
I(d): -
C(d): -
I(t): 626
C(t): 661
I(d): -
C(d): -
I(t): 69.4
C(t): 72.9
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Table 1. Overview of study populations (Continued)
: Ticlopidine
250 mg bd (all
patients)
C(t): Aspirin
325 mg bd (all
patients)
CAPRIE I(d): Clopido-
grel 75 mg
daily (diabetes
patients)
C(d): Aspirin
325 mg daily
(diabetes pa-
tients)
I(t): Clopi-
dogrel 75 mg
daily (all pa-
tients)
C(t): Aspirin
325 mg daily
(all patients)
- I(d): 20%
C(d): 20%
I(t): 9599
C(t): 9586
I(d): 20%
(1920)
C(d): 20%
(1917)
I(t): 9599
C(t): 9586
I(d): -
C(d): -
I(t): 9577
C(t): 9566
I(d): -
C(d): -
I(t): 99.8
C(t): 99.8
CATS I(d): Ticlopi-
dine 250 mg
bd (diabetes
patients)
C(d): Placebo
(diabetes pa-
tients)
I(t)
: Ticlopidine
250 mg bd (all
patients)
C(t): Placebo
(all patients)
- I(d): 172
C(d): 163
I(t): 525
C(t): 528
I(d): 172
C(d): 163
I(t): 519
C(t): 515
I(d): -
C(d): -
I(t): 287
C(t): 364
I(d): -
C(d): -
I(t): 54.7
C(t): 68.9
CHARISMA I(d): Clopido-
grel 75
mg daily and
aspirin 75 to
162 mg daily
(diabetes pa-
tients)
C(d): Aspirin
75 to 162 mg
daily (diabetes
patients)
I(t): Clopido-
- I(d): 3304
C(d): 3252
I(t): 7802
C(t): 7801
I(d): 3304
C(d): 3252
I(t): 7802
C(t): 7801
I(d): -
C(d): -
I(t): 79.6%
C(t): 81.8%
I(d): -
C(d): -
I(t): 79.6
C(t): 81.8
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Table 1. Overview of study populations (Continued)
grel 75
mg daily and
aspirin 75 to
162 mg daily
(all patients)
C(t): Aspirin
75 to 162 mg
daily (all pa-
tients)
CURE I(d): Clopido-
grel 75
mg daily and
aspirin 75 to
300 mg daily
(diabetes pa-
tients)
C(d): Aspirin
75 to 300 mg
daily (diabetes
patients)
I(t): Clopido-
grel 75
mg daily and
aspirin 75 to
300 mg daily
(all patients)
C(t): Aspirin
75 to 300 mg
daily (all pa-
tients)
- I(d): 1405
C(d): 1435
I(t): 6259
C(t): 6303
I(d): 1405
C(d): 1435
I(t): 6259
C(t): 6303
I(d): -
C(d): -
I(t): 78.9%
C(t): 81.2%
I(d): -
C(d): -
I(t): 78.9
C(t): 81.2
Park I(d): Clopido-
grel 75
mg daily and
aspirin 100 to
200 mg daily
(diabetes pa-
tients)
C(d): Aspirin
100 to 200 mg
daily (diabetes
patients)
I(t): Clopido-
grel 75
mg daily and
aspirin 100 to
200 mg daily
(all patients)
- I(d): 340
C(d): 364
I(t): 1357
C(t): 1344
- I(d): -
C(d): -
I(t): 327
C(t): 313
-
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Table 1. Overview of study populations (Continued)
C(t): Aspirin
100 to 200 mg
daily (all pa-
tients)
PRoFESS I(d): Clopido-
grel 75 mg
daily (diabetes
patients)
C(d): Aspirin/
dipyridamole
25 mg/200
mg bd (dia-
betes patients)
I(t): Clopi-
dogrel 75 mg
daily (all pa-
tients)
C(t): Aspirin/
dipyridamole
25 mg/
200 mg bd (all
patients)
- I(d): 2840
C(d): 2903
I(t): 10.151
C(t): 10.181
I(d): 2840
C(d): 2903
I(t): 10.151
C(t): 10.181
I(d): -
C(d): -
I(t): 7736
C(t): 7095
I(d): -
C(d): -
I(t): 76.2
C(t): 69.7
TASS I(d): Ticlopi-
dine 250 mg
bd (diabetes
patients)
C(d): Aspirin
650 mg bd
(diabetes pa-
tients)
I(t)
: Ticlopidine
250 mg bd (all
patients)
C(t): Aspirin
650 mg bd (all
patients)
- I(d): 291
C(d): 306
I(t): 1529
C(t): 1540
I(d): -
C(d): -
I(t): 1529
C(t): 1540
I(d): -
C(d): -
I(t): 828
C(t): 941
I(d): -
C(d): -
I(t): 54.2
C(t): 61.1
Total All interven-
tions
(diabetes pa-
tients)
8711
(and CAPRIE
participants)
All controls
(diabetes pa-
tients)
8802
(and CAPRIE
participants)
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Table 1. Overview of study populations (Continued)
All interven-
tions (all pa-
tients)
38,124
All controls
(all patients)
38,190
All interven-
tions and con-
trols
(diabetes pa-
tients)
21,379
All interven-
tions and con-
trols (all pa-
tients)
76,314
“-” denotes not reported
Abbreviations:
bd: twice daily; C: control; C(d): intervention (diabetes patients); C(t): intervention (all patients); I: intervention; I(d): intervention
(diabetes patients); I(t): intervention (all patients); ITT: intention-to-treat
A P P E N D I C E S
Appendix 1. Search strategies
Search terms and databases
Unless otherwise stated, search terms are free text terms.
Abbreviations:
’$’: stands for any character; ’?’: substitutes one or no character; adj: adjacent (i.e. number of words within range of search term); exp:
exploded MeSH; MeSH: medical subject heading (MEDLINE medical index term); pt: publication type; sh: MeSH; tw: text word
The Cochrane Library
#1 MeSH descriptor Diabetes mellitus, type 2 explode all trees
#2 (obes* in All Text near/6 diabet* in All Text)
#3 (MODY in All Text or NIDDM in All Text or TDM2 in All Text or TD2 in All Text)
#4 ( (non in All Text and insulin* in All Text and depend* in All Text) or (noninsulin* in All Text and depend* in All Text) or (non
in All Text and insulindepend* in All Text) or noninsulindepend* in All Text)
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(Continued)
#5 (typ? in All Text and (2 in All Text near/6 diabet* in All Text) )
#6 (typ? in All Text and (II in All Text near/6 diabet* in All Text) )
#7 (non in All Text and (keto* in All Text near/6 diabet* in All Text) )
#8 (nonketo* in All Text near/6 diabet* in All Text)
#9 (adult* in All Text near/6 diabet* in All Text)
#10 (matur* in All Text near/6 diabet* in All Text)
#11 (late in All Text near/6 diabet* in All Text)
#12 (slow in All Text near/6 diabet* in All Text)
#13 (stabl* in All Text near/6 diabet* in All Text)
#14 (insulin* in All Text and (defic* in All Text near/6 diabet* in All Text) )
#15 (plurimetabolic in All Text and syndrom* in All Text)
#16 (pluri in All Text and metabolic in All Text and syndrom* in All Text)
#17 (typ?2 in All Text near/3 diabet* in All Text)
#18 (keto in All Text and (resist* in All Text near/3 diabet* in All Text) )
#19 (non in All Text and (keto* in All Text near/3 diabet* in All Text) )
#20 (nonketo* in All Text near/3 diabet* in All Text)
#21 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or
#20)
#22 MeSH descriptor Ticlopidine explode all trees
#23 (ticlopidin* in All Text or clopidogrel in All Text or prasugrel in All Text or ticagrelor in All Text)
#24 (ticlodone in All Text or ticlodix in All Text or ticlid in All Text)
#25 (#22 or #23 or #24)
#26 (#21 and #25)
Medline
1 exp Diabetes Mellitus, Type 2/
2 exp Insulin Resistance/
3 exp Glucose Intolerance/
4 exp Metabolic Syndrome X/
5 (impaired glucos$ toleranc$ or glucos$ intoleranc$ or insulin resistan$).tw,ot.
6 (obes$ adj3 diabet$).tw,ot.
7 (MODY or NIDDM or T2DM or T2D).tw,ot.
8 (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non insulin?depend$).tw,ot.
9 ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet$).tw,ot.
10 ((keto?resist$ or non?keto$) adj6 diabet$).tw,ot.
11 (((late or adult$ or matur$ or slow or stabl$) adj3 onset) and diabet$).tw,ot.
12 metabolic syndrom*.tw,ot.
13 or/1-12
14 exp Diabetes Insipidus/
15 diabet$ insipidus.tw,ot.
16 14 or 15
17 13 not 16
18 exp Ticlopidine/
19 (ticlopidin* or clopidogrel or prasugrel).tw,ot.
20 (ADP adj3 receptor antagonist*).tw,ot.
21 (ticlodone or ticlodix or ticlid).tw,ot.
22 or/18-21
23 17 and 22
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(Continued)
24 randomized controlled trial.pt.
25 controlled clinical trial.pt.
26 randomi?ed.ab.
27 placebo.ab.
28 drug therapy.fs.
29 randomly.ab.
30 trial.ab.
31 groups.ab.
32 or/24-31
33 Meta-analysis.pt.
34 exp Technology Assessment, Biomedical/
35 exp Meta-analysis/
36 exp Meta-analysis as topic/
37 hta.tw,ot.
38 (health technology adj6 assessment$).tw,ot.
39 (meta analy$ or metaanaly$ or meta?analy$).tw,ot.
40 ((review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo
or psyclit or healthstar or biosis or current content$ or systemat$)).tw,ot.
41 or/33-40
42 32 or 41
43 (comment or editorial or historical-article).pt.
44 42 not 43
45 23 and 44
Embase
1 exp Diabetes Mellitus, Type 2/
2 exp Insulin Resistance/
3 (MODY or NIDDM or T2D or T2DM).tw,ot.
4 ((typ? 2 or typ? II or typ?II or typ?2) adj3 diabet*).tw,ot.
5 (obes* adj3 diabet*).tw,ot.
6 (non insulin* depend* or non insulin?depend* or noninsulin* depend* or noninsulin?depend*).tw,ot.
7 ((keto?resist* or non?keto*) adj3 diabet*).tw,ot.
8 ((adult* or matur* or late or slow or stabl*) adj3 diabet*).tw,ot.
9 (insulin* defic* adj3 relativ*).tw,ot.
10 (insulin* resistanc* or impaired glucos* toleranc* or glucos* intoleranc*).tw,ot.
11 or/1-10
12 exp Diabetes Insipidus/
13 diabet* insipidus.tw,ot.
14 12 or 13
15 11 not 14
16 exp ticlopidine/
17 exp clopidogrel/
18 exp prasugrel/
19 exp ticagrelor/
20 (ADP adj3 receptor antagonist*).tw,ot.
21 (ticlopidin* or clopidogrel or prasugrel or ticagrelor).tw,ot.
22 (ticlodone or ticlodix or ticlid).tw,ot.
23 or/16-22
24 15 and 23
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(Continued)
25 exp Randomized Controlled Trial/
26 exp Controlled Clinical Trial/
27 exp Clinical Trial/
28 exp Comparative Study/
29 exp Drug comparison/
30 exp Randomization/
31 exp Crossover procedure/
32 exp Double blind procedure/
33 exp Single blind procedure/
34 exp Placebo/
35 exp Prospective Study/
36 ((clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).ab,ti.
37 (random$ adj6 (allocat$ or assign$ or basis or order$)).ab,ti.
38 ((singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).ab,ti.
39 (cross over or crossover).ab,ti.
40 or/25-39
41 exp meta analysis/
42 (metaanaly$ or meta analy$ or meta?analy$).ab,ti,ot.
43 ((review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo
or psyclit or healthstar or biosis or current content$ or systematic$)).ab,ti,ot.
44 exp Literature/
45 exp Biomedical Technology Assessment/
46 hta.tw,ot.
47 (health technology adj6 assessment$).tw,ot.
48 or/41-47
49 40 or 48
50 (comment or editorial or historical-article).pt.
51 49 not 50
52 24 and 51
53 review.pt.
54 52 not 53
Appendix 2. Baseline characteristics
Study ID
Character-
istic
AAASPS CAPRIE CATS
CHARISMA
CURE Park PRoFESS TASS
Interven-
tion(s) and
control(s)
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
325 mg bd
I: Clopido-
grel 75 mg
daily
C:
Aspirin 325
mg daily
I: Ticlopi-
dine 250 mg
bd
C: Placebo
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
162 mg
daily
C: Aspirin
75 to 162
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
300 mg
daily
C: Aspirin
75 to 300
I: Clopido-
grel 75 mg
daily and as-
pirin 100 to
200 mg
daily
C
(d): Aspirin
I: Clopido-
grel 75 mg
daily
C: Aspirin /
dipyri-
damole
25 mg / 200
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
650 mg bd
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(Continued)
mg daily mg daily 100 to 200
mg daily
mg bd
Partici-
pating pop-
ulation
Patients
with cere-
bral infarcts
Patients
with vascu-
lar disease
Patients
with
thrombo-
embolic
strokes
High-
risk vascular
patients
Patients
with acute
coronary
syndrome
Patients
with
drug eluding
stents
Patients
with
ischaemic
strokes
Patients
with
ischaemic
neurological
events
Country USA 16 countries USA,
Canada
32 countries 28 countries South Korea 35 countries USA,
Canada
Setting Hospi-
tal and com-
munity
Hospi-
tal and com-
munity
Hospital in-
patients
Hospital Hospital In-
patients and
community
Hospi-
tal and com-
munity
Hospi-
tal and com-
munity
Sex
[female%]
I: 54.5
C: 52.4
I: 28
C: 28
I: 40
C: 37
I: 29.7
C: 29.8
I: 38.7
C: 38.3
I: 30.0
C: 30.6
I: 36.0
C: 35.9
I: 36
C: 35
Age [mean
years (SD)]
I: 60.9 (10.
7)
C: 61.6 (10.
4)
I: 62.5 (11.
1)
C: 62.5 (11.
1)
I: 66
C: 65
Median
I: 64.0
C: 64.0
I: 64.2 (11.
3)
C: 64.2 (11.
3)
I: 62 (9.8)
C: 61.9 (9.
9)
I: 66.2 (8.5)
C: 66.1 (8.
6)
I: 62.7 (9.4)
C: 63.2 (9.
3)
HbA1c
[mean %
(SD)]
- - - - - - - -
BMI [mean
kg/m2 (SD)
]
I: 29.9 (7.1)
C: 30.0 (6.
8)
- - - - - I: 26.8 (5.0)
C: 26.8 (5.
0)
-
Ethnic
groups [%]
I: African
American
C: African
American
- Caucasian
I: 73%
C: 71%
White
I: 80.4%
C: 79.9%
- - White / Eu-
ropean
I: 57.3%
C: 57.7%
White
I: 80%
C: 81%
Duration of
follow-up
(mean)
I: 710 days
C: 716 days
I: 1.91 years
C: 1.91
years
I: 17months
C: 19
months
Median
I: 28months
C: 28
months
I: 12months
C: 12
months
I: 19.2
months
C: 19.2
months
I: 2.5 years
C: 2.5 years
I: 778 days
C: 858 days
Footnotes
“-” denotes not reported
Abbreviations:
bd: twice daily; BMI: body mass index; C: control; C(d): intervention (diabetes patients); C(t): intervention (all patients); HbA1c:
glycosylated haemoglobin A1c; I: intervention; I(d): intervention (diabetes patients); I(t): intervention (all patients); SD: standard
deviation
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Appendix 3. Study outcomes
Study ID
Character-
istic
AAASPS CAPRIE CATS
CHARISMA
CURE Park PRoFESS TASS
Interven-
tion(s) and
control(s)
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
325 mg bd
I: Clopido-
grel 75 mg
daily
C:
Aspirin 325
mg daily
I: Ticlopi-
dine 250 mg
bd
C: Placebo
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
162 mg
daily
C: Aspirin
75 to 162
mg daily
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
300 mg
daily
C: Aspirin
75 to 300
mg daily
I: Clopido-
grel 75 mg
daily and as-
pirin 100 to
200 mg
daily
C
(d): Aspirin
100 to 200
mg daily
I: Clopido-
grel 75 mg
daily
C: Aspirin /
dipyri-
damole
25 mg / 200
mg bd
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
650 mg bd
All-cause
mortality
I(d): -
C(d): -
I(t): 45
C(t): 40
I(d): -
C(d): -
I(t): 560
C(t): 571
I(d): 30
C(d): 23
I(t): 66
C(t): 65
I(d): -
C(d): -
I(t): 371
C(t): 374
I(d): -
C(d): -
I(t): 359
C(t): 390
I(d): -
C(d): -
I(t): 20
C(t): 13
I(d): -
C(d): -
I(t): 756
C(t): 739
I(d): -
C(d): -
I(t): 175
C(t): 196
Vascular
mortality
I(d): -
C(d): -
I(t): 18
C(t): 18
I(d): -
C(d): -
I(t): 350
C(t): 378
I(d): 18
C(d): 18
I(t): 35
C(t): 43
I(d): -
C(d): -
I(t): 238
C(t): 229
I(d): -
C(d): -
I(t): 318
C(t): 345
- - I(d): -
C(d): -
I(t): 120
C(t): 116
My-
ocardial in-
farction (fa-
tal)
I(d): -
C(d): -
I(t): 1
C(t): 0
I(d): -
C(d): -
I(t): 53
C(t): 75
I(d): 13
C(d): 10
I(t): 21
C(t): 22
- - - - I(d): -
C(d): -
I(t): 21
C(t): 14
Myocar-
dial infarc-
tion (non-
fatal)
I(d): -
C(d): -
I(t): 8
C(t): 8
I(d): -
C(d): -
I(t): 255
C(t): 301
I(d): 3
C(d): 9
I(t): 11
C(t): 15
I(d): -
C(d): -
I(t): 146
C(t): 155
- - - -
My-
ocardial in-
farction (fa-
tal andnon-
fatal)
I(d): -
C(d): -
I(t): 9
C(t): 8
I(d): -
C(d): -
I(t): 308
C(t): 376
I(d): 16
C(d): 19
I(t): 32
C(t): 37
- I(d): -
C(d): -
I(t): 324
C(t): 419
I(d): -
C(d): -
I(t): 10
C(t): 7
I(d): -
C(d): -
I(t): 197
C(t): 178
-
Stroke (fa-
tal)
I(d): -
C(d): -
I(t): 4
C(t): 2
I(d): -
C(d): -
I(t): 37
C(t): 42
I(d): 6
C(d): 9
I(t): 14
C(t): 17
- - - - I(d): -
C(d): -
I(t): 16
C(t): 23
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Stroke
(non-fatal)
I(d): -
C(d): -
I(t): 102
C(t): 84
I(d): -
C(d): -
I(t): 472
C(t): 504
I(d): 28
C(d): 32
I(t): 67
C(t): 86
I(d): -
C(d): -
I(t): 150
C(t): 189
- - - I(d): -
C(d): -
I(t): 156
C(t): 189
Stroke (fa-
tal andnon-
fatal)
I(d): -
C(d): -
I(t): 106
C(t): 86
I(d): -
C(d): -
I(t): 509
C(t): 546
I(d): 34
C(d): 41
I(t): 81
C(t): 103
- I(d): -
C(d): -
I(t): 75
C(t): 87
I(d): -
C(d): -
I(t): 9
C(t): 4
I(d): 334
C(d): 312
I(t): 862
C(t): 879
I(d): 25
C(d): 44
I(t): 172
C(t): 212
Footnotes
“-” denotes not reported
Abbreviations:
bd: twice daily; C: control; C(d): intervention (diabetes patients); C(t): intervention (all patients); I: intervention; I(d): intervention
(diabetes patients); I(t): intervention (all patients)
Appendix 4. Adverse events
Study ID
Character-
istic
AAASPS CAPRIE CATS
CHARISMA
CURE Park PRoFESS TASS
Interven-
tion(s) and
control(s)
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
325 mg bd
I: Clopido-
grel 75 mg
daily
C:
Aspirin 325
mg daily
I: Ticlopi-
dine 250 mg
bd
C: Placebo
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
162 mg
daily
C: Aspirin
75 to 162
mg daily
I: Clopido-
grel 75 mg
daily and as-
pirin 75 to
300 mg
daily
C: Aspirin
75 to 300
mg daily
I: Clopido-
grel 75 mg
daily and as-
pirin 100 to
200 mg
daily
C
(d): Aspirin
100 to 200
mg daily
I: Clopido-
grel 75 mg
daily
C: Aspirin /
dipyri-
damole
25 mg / 200
mg bd
I: Ticlopi-
dine 250 mg
bd
C: Aspirin
650 mg bd
Serious ad-
verse events
(including
bleeding)
I(d): -
C(d): -
I(t): 270
C(t): 262
I(d): -
C(d): -
I(t): 360
C(t): 409
I(d): -
C(d): -
I(t): 43
C(t): 15
- - - I(d): -
C(d): -
I(t): 373
C(t): 426
-
Serious
bleeding
I(d): -
C(d): -
I(t): 10
C(t): 19
I(d): -
C(d): -
I(t): 77
C(t): 109
I(d): -
C(d): -
I(t): 2
C(t): 1
I(d): -
C(d): -
I(t): 130
C(t): 104
I(d): -
C(d): -
I(t): 231
C(t): 169
I(d): -
C(d): -
I(t): 3
C(t): 1
I(d): -
C(d): -
I(t): 116
C(t): 128
I(d): -
C(d): -
I(t): 137
C(t): 152
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Footnotes
“-” denotes not reported
Abbreviations:
bd: twice daily; C: control; C(d): intervention (diabetes patients); C(t): intervention (all patients); I: intervention; I(d): intervention
(diabetes patients); I(t): intervention (all patients)
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